Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lipid Management in Renal Transplant Recipients: a Pilot Study Evaluating the Use of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitor Evolocumab.

NCT04608474 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04608474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lipid Management in Renal Transplant Recipients: a Pilot Study Evaluating the Use of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitor Evolocumab.
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Completed
Start date
February 17, 2021
Completion date
May 14, 2025
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemias